Introduction {#s1}
============

Stroke is the most prevalent cardiovascular-related condition in Japan. The Hisayama study was started as a population-based prospective cohort study of cerebrovascular and cardiovascular diseases in 1961 in the town of Hisayama. Most of the deceased subjects of the study underwent an autopsy examination. Changes in stroke trends in the last 50 years were clarified by comparing the data from different study cohorts registered every 13 to 14 years. The Suita study was based on a random sampling of Japanese urban residents. Several reports from this study showed the significance of pre-hypertension as well as hypertension as a risk factor for stroke alone and in combination with other underlying characteristics. Stroke is a leading cause of functional dependence and death \[[@R01]\]. The intima-media thickness (IMT) can be quantified using conventional echography. A number of studies have described the relationship between IMT and the risk of myocardial infarction and stroke \[[@R02], [@R03]\].

Apolipoprotein A1 (ApoA1) plays a major role in reverse cholesterol transport, while apolipoprotein B (ApoB) contributes to the accumulation of cholesterol in plaque \[[@R04], [@R05]\]. A meta-analysis suggested that reduced ApoA1 levels, increased ApoB levels, and an increased ApoB/A1 ratio are risk factors of ischemic but not hemorrhagic stroke. Elevated ApoA1 levels may be a risk factor of hemorrhagic stroke \[[@R06]\]. ApoA1 and paraoxonase-1 levels may be clinically useful for the diagnosis of ischemic stroke and for differentiating between ischemic and hemorrhagic strokes \[[@R07]\]. However, the association between ApoA1 levels and plaque properties in patients with atherothrombotic infraction (ATBI) is not clear. This study aimed to investigate the association between serum ApoA1 levels and the characteristics of carotid plaque on ultrasonography among the ischemic stroke subtypes.

Materials and Methods {#s2}
=====================

Study design and patient population {#s2a}
-----------------------------------

We prospectively enrolled 92 patients with stroke and 21 age-matched controls (CONT) between January 1, 2017, and June 30, 2018, at the National Hospital Organization Kyoto Medical Center in Kyoto, Japan ([Table 1](#T1){ref-type="table"}). Brain infarction was classified into at least three different stroke subtypes: ATBI, cardioembolic infarction (CE), and lacunar infarction (LI) \[[@R08]\]. The inclusion and exclusion criteria in age-matched controls were 20 years of or older and visiting Neurology Clinics at our hospitals. Exclusion criteria include patients without informed consent agreement. Medical history and laboratory data were obtained from patient's medical records. Diabetes was defined according to the Japan Diabetes Society \[[@R9]\]. Weekly alcohol intake in units of "go" (a traditional Japanese unit of volume corresponding to 23 g of ethanol) was obtained from patients, which was then converted to grams of ethanol per day. One go is 180 mL of sake and corresponds to 1 bottle (633 mL) of beer, two single shots (75 mL) of whiskey, or two glasses (180 mL) of wine. Participants consuming more than 0.3 go per week were regarded as current alcohol drinkers \[[@R10]\]. The study was approved by the Kyoto Medical Center Ethics Committee, Japan (approval number: 18-084). The study protocol conformed to the ethical guidelines of the 2013 Declaration of Helsinki.

###### Clinical Characteristics of the Participants in the ATBI, CE, LI, and Control Groups

                               ATBI (n = 52)   CE (n = 15)    LI (n = 25)    CONT (n = 21)
  ---------------------------- --------------- -------------- -------------- ---------------
  Age, years                   69.7 ± 10.4     66.0 ± 12.3    71.9 ± 9.8     67.5 ± 8.0
  Female, %                    55.8            60.0           68.0           38.1
  BMI, kg/m^2^                 23.5 ± 3.3      22.5 ± 3.6     22.1 ± 2.6     23.4 ± 3.5
  SBP, mm Hg                   131.7 ± 17.9    127.5 ± 17.6   134.7 ± 21.4   132.7 ± 13.5
  DBP, mm Hg                   73.3 ± 11.6     75.3 ± 8.3     72.6 ± 12.2    74.4 ± 11.9
  Current smoker, %            33.3            20.0           28.0           14.3
  Current alcohol drinker, %   37.3            53.3           36.0           19.0
  Hypertension, %              94.2^b^         60.0           80.0           81.0
  Diabetes, %                  34.6            6.7            28.0           20.0
  Hyperlipidemia, %            78.8^c^         60.0^c^        96.0^a^        61.9
  Atrial fibrillation, %       7.7^b^          100.0^a,\ c^   4.0            4.8
  Statin, %                    84.6^c^         53.8           50.0           66.7

^a^P \< 0.05, vs. CONT, ^b^P \< 0.05, vs. CE, ^c^P \< 0.05, vs. LI. ATBI: atherothrombotic infarction; CE: cardioembolic infarction; LI: lacuna infraction; CONT: control; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure.

Ultrasound evaluation {#s2b}
---------------------

High-resolution B-mode ultrasonography was performed by trained sonographers using a 7.5-MHz linear array ultrasound imaging system (SSD-2000, Aloka Co. Ltd., Tokyo, Japan). The left and right carotid arteries were scanned with the beam focused on the near and far walls of the distal 2 cm of the common carotid artery proximal to its bifurcation. Both longitudinal and transverse images were obtained to assess the plaque. IMT at the common carotid artery (CCA), carotid bifurcation (BIF), and the internal carotid artery (ICA) were measured. All measurements were made using electronic calipers. The plaque was classified into three categories: 1) Soft plaque-lesion echogenicity less than that of the surrounding adventitia for more than 80% of the plaque area without calcium; 2) Hard plaque-lesion echogenicity was greater than or equal to that of the surrounding adventitia for more than 80% of the plaque area without calcium; 3) Intermediate plaque \[[@R11]\]. Significant stenosis was defined as a diameter reduction of \> 80%. The end-diastolic velocity (EDV), peak systolic velocity (PSV), mean velocity (mean V), and pulsatility index (PI) were measured.

Laboratory data {#s2c}
---------------

Blood samples were collected, and total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and lipoprotein(a) (Lp(a)) levels were measured. Serum levels of ApoA1, A2, B, C2, C3, and E were measured at BML, Inc. (Tokyo, Japan). ApoA1 was evaluated by turbidimetric immunoassay using a commercially available kit (ApoA-I Auto-N' Daiichi', Sekisui Medical Co., Ltd., Tokyo, Japan).

Statistical analyses {#s2d}
--------------------

All analyses were performed using SSPS for Windows (ver. 24.0; SSPS Inc., Chicago, IL, USA). Continuous variables are presented as the mean ± standard deviation (SD) and categorical variables as counts and percentages. Pearson's Chi-square test was used to compare continuous variables, and one-way factorial analysis of variance (ANOVA) was used for categorical data after testing the normality of the data. Then, the differences were analyzed using *post hoc* Tukey-HSD or Games-Howell multiple comparison tests depending on the results of the assumption of the homogeneity of variances (Levene test). A P value of \< 0.05 was considered statistically significant.

Results {#s3}
=======

Background characteristics of the control and stroke patients {#s3a}
-------------------------------------------------------------

The background characteristics of the control subjects and stroke patients are summarized in [Table 1](#T1){ref-type="table"}. There were no differences in the prevalence of hypertension, diabetes mellitus, atrial fibrillation, current alcohol drinking, and current smoking among the four groups.

Blood analysis and ultrasound evaluation {#s3b}
----------------------------------------

There was no difference in the TC, LDL-C, HDL-C, and ApoB levels among the four groups ([Table 2](#T2){ref-type="table"}). The serum ApoA1 levels in the ATBI group were significantly lower compared with the CONT group. Among the ATBI group, the serum ApoA1 levels in the low-intensity plaque-type were significantly lower than those in the intermediate or hard-intensity plaques. Furthermore, the serum ApoA1 levels in the soft plaque-type were significantly lower than those in the intermediate type ([Table 3](#T3){ref-type="table"}). Among the ATBI group, ApoA1 levels in the heterogeneous type were significantly lower than those in the homogeneous type ([Table 4](#T4){ref-type="table"}).

###### Serum Lipids and Apolipoproteins of the Participants in the ATBI, CE, LI, and Control Groups

                    ATBI (n = 52)     CE (n = 15)     LI (n = 25)    CONT (n = 21)
  ----------------- ----------------- --------------- -------------- ---------------
  Serum lipids                                                       
    TC, mg/dL       178.4 ± 43.0      195.3 ± 35.8    195.6 ± 55.4   205.6 ± 29.7
    LDL-C, mg/dL    106.8 ± 29.7      113.1 ± 27.1    121.0 ± 39.6   118.6 ± 32.2
    MDA-LDL, U/L    103.8 ± 44.7      130.7 ± 48.9    100.8 ± 45.1   92.4 ± 18.5
    HDL-C, mg/dL    54.6 ± 12.5       57.5 ± 19.4     66.2 ± 17.1    67.0 ± 23.7
    TG, mg/dL       147.9 ± 84.2      161.7 ± 107.9   128.5 ± 82.2   142.5 ± 62.9
    RLP-C, mg/dL    6.7 ± 7.0         10.0 ± 7.5      7.1 ± 5.1      6.8 ± 3.2
    Lp(a), mg/dL    18.0 ± 21.7       21.3 ± 33.5     29.1 ± 44.2    14.8 ± 12.0
  Apolipoproteins                                                    
    ApoA1, mg/dL    128.6 ± 19.6^a^   131.9 ± 25.3    139.2 ± 17.1   149.3 ± 21.5
    ApoA2, mg/dL    27.9 ± 4.9        30.2 ± 5.5      27.4 ± 4.3     30.1 ± 4.7
    ApoB, mg/dL     79.1 ± 17.3       89.2 ± 16.6     80.6 ± 29.1    76.5 ± 9.2
    ApoC2, mg/dL    4.5 ± 1.7         5.9 ± 2.3       4.7 ± 2.4      4.9 ± 1.7
    ApoC3, mg/dL    9.9 ± 4.3         11.2 ± 3.5      9.9 ± 3.4      10.7 ± 3.0
    ApoE, mg/dL     3.1 ± 1.2         3.7 ± 1.2       3.4 ± 1.3      3.4 ± 0.8
  HbA1c, %          6.6 ± 1.5         6.0 ± 1.8       6.4 ± 1.3      6.1 ± 0.7

^a^P \< 0.05, vs. CONT. ATBI: atherothrombotic infarction; CE: cardioembolic infarction; LI: lacuna infraction; CONT: control; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; MDA-LDL: malondialdehyde-modified low-density lipoprotein; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride; RLP-C: remnant lipoprotein cholesterol; Lp(a): lipoprotein(a); ApoA1: apolipoprotein A1; ApoA2: apolipoprotein A2; ApoB: apolipoprotein B; ApoC1: apolipoprotein C1; ApoC2: apolipoprotein C2; ApoE: apolipoprotein E; HbA1c: hemoglobin A1c.

###### Ultrasound Evaluation of the ATBI, CE, LI, and Control Groups

  Variables                  ATBI                   CE            LI            CONT
  -------------------------- ---------------------- ------------- ------------- -------------
  CCA, number of plaques     1.5 ± 1.5^a,\ b,\ c^   0.0 ± 0.0     0.3 ± 1.0     0.2 ± 0.7
  CCA plaque thickness, mm   2.2 ± 1.1              \-            2.9           1.4, 2.0
  BIF, number of plaques     2.1 ± 1.3^a,\ b,\ c^   0.3 ± 1.0     0.7 ± 1.3     0.3 ± 1.0
  BIF plaque thickness, mm   2.2 ± 1.1              2.9           2.2 ± 0.9     1.9, 2.2
  ICA, number of plaques     1.7 ± 1.3^a,\ b,\ c^   0.1± 0.5      0.5 ± 0.9     0.1 ± 0.5
  ICA plaque thickness, mm   2.5 ± 1.1              2             2.2 ± 0.9     2.3
  Significant stenosis,%     13.7^a,\ b,\ c^        0             0             0
  PSV, cm/s                  62.2 ± 19.4            55.6 ± 10.1   69.8 ± 18.0   65.3 ± 19.6
  EDV, cm/s                  14.2 ± 5.3             13.2 ± 2.9    13.8 ± 3.5    16.5 ± 5.9
  Mean V, cm/s               25.6 ± 7.2             23.9 ± 3.6    28.0 ± 6.3    30.4 ± 8.5
  PI                         2.4 ± 2.0              1.8 ± 0.4     2.0 ± 0.4     1.7 ± 0.7
  Mean IMT of CCA, mm        0.9 ± 0.3              0.8 ± 0.1     0.8 ± 0.2     0.8 ± 0.2
  Plaque category                                                               
    Non-plaque, %            5.9^a,\ b,\ c^         86.7          62.5          89.5
    Soft, %                  17.6^a,\ b,\ c^        0             0             0
    Intermediate, %          39.2^a,\ b,\ c^        6.7           16.7          10.5
    Hard, %                  37.3^a,\ b,\ c^        6.7           20.8          0

^a^P \< 0.05, vs. CONT, ^b^P \< 0.05, vs. CE, ^c^P \< 0.05, vs. LI. ATBI: atherothrombotic infraction; CE: cardioembolic infarction; LI: lacuna infraction; CONT: control; CCA: common carotid artery; BIF: carotid bifurcation; ICA: internal carotid artery; EDV: end-diastolic velocity; PSV: peak systolic velocity; mean V: mean velocity; PI: pulsatility index; IMT: intra-media thickness.

###### Serum Lipids and Apolipoproteins Between the Heterogeneous and Homogeneous Type in the ATBI Group

  Variables         Heterogeneous type (n = 21 )   Homogenous type (n = 27)
  ----------------- ------------------------------ --------------------------
  Serum lipids                                     
    TC, mg/dL       170.0 ± 23.2^a^                188.4 ± 39.3
    LDL-C, mg/dL    98.0 ± 23.2                    113.6 ± 31.6
    MDA-LDL, U/L    87.0 ± 33.3^a^                 116.9 ± 50.3
    HDL-C, mg/dL    53.6 ± 13.7                    54.3 ± 10.9
    TG, mg/dL       123.2 ± 43.4                   153.7 ± 92.0
    RLP-C, mg/dL    7.0 ± 8.9                      5.8 ± 4.0
    Lp (a), mg/dL   28.3 ± 28.5^a^                 10.6 ± 9.4
  Apolipoproteins                                  
    ApoA1, mg/dL    121.0 ± 19.6^a^                133.8 ± 19.2
    ApoA2, mg/dL    26.0 ± 4.2^a^                  29.3 ± 5.4
    ApoB, mg/dL     74.7 ± 15.9                    82.4 ± 18.4
    ApoC2, mg/dL    4.2 ± 1.8                      4.7 ± 1.5
    ApoC3, mg/dL    8.6 ± 3.4                      10.4 ± 4.4
    ApoE, mg/dL     2.8 ± 0.9                      3.2 ± 1.3
  HbA1c, %          6.6 ± 1.3                      6.5 ± 1.6

^a^P \< 0.05, vs. homogenous type. ATBI: atherothrombotic infraction; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; MDA-LDL: malondialdehyde-modified low-density lipoprotein; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride; RLP-C: remnant lipoprotein cholesterol; Lp(a): lipoprotein(a); ApoA1: apolipoprotein A1; ApoA2: apolipoprotein A2; ApoB: apolipoprotein B; ApoC1: apolipoprotein C1; ApoC2: apolipoprotein C2; ApoE: apolipoprotein E; HbA1c: hemoglobin A1c.

Discussion {#s4}
==========

Main findings {#s4a}
-------------

We found that the ApoA1 levels in the ATBI group were significantly lower than those in the CONT group, although there was no difference in the HDL-C levels between the groups.

ApoA1 is the primary lipoprotein associated with HDL in plasma \[[@R12]\]. Lower ApoA1 levels have been found to be associated with a higher stroke risk \[[@R13]\]. In metabolic syndrome, lower levels of HDL-C and ApoA1 were associated with carotid plaques \[[@R14]\]. Our findings support the results of these prior studies. The mechanism of ATBI caused by reduced ApoA1 levels is unknown. The concentration of ApoA1 in the artery wall is thought to enhance cellular cholesterol efflux and protect against atherosclerosis. ApoA1 production by macrophages in the arterial wall is protective against atherosclerosis in mice \[[@R15]\]. Furthermore, ApoA1 levels were associated with plaque properties in the ATBI group. Contrast-enhanced ultrasonography of the carotid artery is a relatively novel diagnostic tool that exploits resonated ultrasound waves from circulating microbubbles. This property permits vascular visualization by producing superior angiography-like images and allows the identification of *vasa vasorum* and intraplaque microvessels \[[@R16]\]. Further examination, including contrast-enhanced ultrasonography, is needed to clarify the mechanism.

Strengths and limitations {#s4b}
-------------------------

The strengths of the present study include that the ultrasound evaluation was undertaken by trained sonographers in a real-world setting. There were several limitations to the present study. First, this was a single-center study with a relatively small sample size. There was no difference in ApoA1 levels between CE and CONT. Careful attention should be paid for interpreting the results, because the smaller sample size in CE (n = 15) compared with the larger sample size in ATBI (n = 52). Second, there are several confounding factors such as age, body mass index (BMI), smoking, and complications. However, we did not analyze controlling for all confounding factors except for age due to the small sample size. Further examination including confounding factors and the large sample are required to clarify these issues in the future. Third, owing to the cross-sectional design, the causal relationship with the determinants could not be ascertained. Fourth, we did not assess the histological characteristics of the carotid plaque. Further examinations, including a histological analysis, are required in the future.

In conclusion, the findings of the current study suggest that serum ApoA1 levels might be associated with the development of ATBI and the plaque properties of the carotid artery.
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